TGTX
TG Therapeutics, Inc.·Healthcare
35.33
3.003%(+1.03)
Market ClosedLast Updated: — ET
52W L: $25.2852W H: $46.48
TGTX NEWS
zacks.com
2d ago
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data expected by late 2026 or early 2027.
globenewswire.com
3d ago
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the Company's anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS). BRIUMVI is currently approved in the United States and several ex-US territories as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in adults with RMS.
seekingalpha.com
Mar 31
TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside
Briumvi's US net product revenues reached $182.7M in Q4'25, with 19.5% sequential growth, and 2026 global revenue guidance is $875M–$900M. Key catalysts include the ENHANCE trial readout (mid-2026) and pivotal subcutaneous Briumvi data (year-end 2026/1Q 2027), both with significant upside potential. TGTX's $300M buyback program could provide downside support, although material negative updates are still a risk even with the buyback program in place.
defenseworld.net
Mar 30
TG Therapeutics, Inc. $TGTX Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase and Co. raised its holdings in TG Therapeutics, Inc. (NASDAQ: TGTX) by 56.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 227,934 shares of the biopharmaceutical company's stock after buying an additional 81,907 shares during the quarter. JPMorgan Chase and
defenseworld.net
Mar 24
1,922,410 Shares in TG Therapeutics, Inc. $TGTX Acquired by Congress Asset Management Co.
Congress Asset Management Co. purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,922,410 shares of the biopharmaceutical company's stock, valued at approximately $57,307,000. Congress Asset Management Co.
globenewswire.com
Mar 19
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives
